Phase III, randomized, open-label study of durvalumab (MEDI4736) monotherapy, or durvalumab + tremelimumab, versus standard of care (SoC), in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): eagle

R. Ferris,C. Even,R. Haddad,M. Tahara,T. Goswami,A. Franks,U. Emeribe,A. Jarkowski,G. Melillo,L. Licitra
DOI: https://doi.org/10.1186/2051-1426-3-S2-P150
2015-11-04
Abstract:
What problem does this paper attempt to address?